Sulindac sulfide–induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2

Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that induces apoptosis in cultured colon cancer cells and in intestinal epithelia in association with its chemopreventive efficacy. Resistance to sulindac is well documented in patients with familial adenomatous polyposis; however, the molecular mechanisms underlying such resistance remain unknown. We determined the effect of ectopic Bcl-2 expression upon sulindac-induced apoptotic signaling in SW480 human colon cancer cells. Sulindac sulfide activated both the caspase-8-dependent and mitochondrial apoptotic pathways. Ectopic Bcl-2 attenuated cytochrome c release and apoptosis induction compared with SW480/neo cells. Coadministration of sulindac sulfide and the small-molecule Bcl-2 inhibitor HA14-1 increased apoptosis induction and enhanced caspase-8 and caspase-9 cleavage, Bax redistribution, and cytochrome c and second mitochondria-derived activator of caspase release. Given that sulindac sulfide activated caspase-8 and increased membrane death receptor (DR4 and DR5) protein levels, we evaluated its combination with the endogenous death receptor ligand tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). Coadministration of sulindac sulfide and TRAIL cooperatively enhanced apoptotic signaling as effectively as did HA14-1. Together, these data indicate that HA14-1 or TRAIL can enhance sulindac sulfide–induced apoptosis and represent novel strategies for circumventing Bcl-2-mediated apoptosis resistance in human colon cancer cells.

[1]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[2]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[3]  F. Sinicrope,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells , 2004, Clinical Cancer Research.

[4]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[5]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[6]  P. Hersey,et al.  TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria1 , 2000, The Journal of Immunology.

[7]  R. K Srivastava,et al.  Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.

[8]  J. Tan,et al.  HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death , 2003, Leukemia.

[9]  D. E. Duggan,et al.  Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. , 1980, Drug metabolism and disposition: the biological fate of chemicals.

[10]  S. Goodman,et al.  Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac , 1999, Gut.

[11]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[12]  F. Sinicrope,et al.  Role of cyclooxygenase-2 in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[13]  G. Thomas,et al.  Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. , 1994, Gut.

[14]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[15]  V. Steele,et al.  Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. , 1997, Cancer research.

[16]  G. Piazza,et al.  A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. , 1997, Gastroenterology.

[17]  Yuri Lazebnik,et al.  Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction* , 2002, The Journal of Biological Chemistry.

[18]  J. Morrow,et al.  Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. , 1999, Neoplasia.

[19]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Giardiello,et al.  Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. , 2001, Gastroenterology.

[21]  Ming Jiang,et al.  Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. , 2003, Genes & development.

[22]  J. Martinou,et al.  Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. , 2001, Molecular cell.

[23]  H. Lynch,et al.  Rectal cancer after prolonged sulindac chemoprevention. A case report , 1995, Cancer.

[24]  D. Hicks,et al.  BCL-2 expression in human colorectal adenomas and carcinomas. , 1994, Oncogene.

[25]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[26]  F. Sinicrope,et al.  Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? , 2005, Seminars in oncology.

[27]  J. Lee,et al.  bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.

[28]  M MacFarlane,et al.  Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[29]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[30]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[31]  M. Bertagnolli,et al.  Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.

[32]  B. Aggarwal,et al.  Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[33]  F. Sinicrope,et al.  Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. , 2002, Cancer research.

[34]  F. Sinicrope,et al.  Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. , 2002, Cancer research.

[35]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[36]  G. Kroemer,et al.  Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. , 1997, Cancer research.

[37]  L. Messerini,et al.  Long‐term treatment with sulindac in familial adenomatous polyposis: Is there an actual efficacy in prevention of rectal cancer? , 2000, Journal of surgical oncology.

[38]  Tao Zhang,et al.  The Chemopreventive Agent Sulindac Attenuates Expression of the Antiapoptotic Protein Survivin in Colorectal Carcinoma Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[39]  E. Slee,et al.  Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release , 2000, Cell Death and Differentiation.

[40]  T. McDonnell,et al.  TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2 , 2001, Oncogene.

[41]  Qin He,et al.  Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. , 2001, Cancer research.

[42]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[43]  M. Bertagnolli,et al.  The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. , 1998, Carcinogenesis.

[44]  B. Rigas,et al.  Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. , 1995, The Journal of clinical investigation.

[45]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[46]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[47]  R. Knight,et al.  IMiDs: a novel class of immunomodulators. , 2005, Seminars in oncology.

[48]  M. Birrer,et al.  N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines , 2004, Cell Death and Differentiation.

[49]  Y. Niv,et al.  Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. , 1994, Gastroenterology.

[50]  Yun Dai,et al.  The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.

[51]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[52]  P. Nicotera,et al.  1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. , 1998, Molecular pharmacology.

[53]  D. Alberts,et al.  Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. , 1995, Cancer research.

[54]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[55]  R. Hanajima,et al.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[57]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[58]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[59]  N. Cheong,et al.  Inhibitor of Apoptosis Proteins Are Substrates for the Mitochondrial Serine Protease Omi/HtrA2* , 2003, Journal of Biological Chemistry.

[60]  K. Kinzler,et al.  Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer , 1992, Molecular and cellular biology.